This roundtable series assesses treatment after first-line progression for patients with deleterious germline or somatic homologous recombination repair-mutated metastatic castration-resistant prostate cancer, as discussed by key opinion leaders and participants at virtual live events.

Options Post First-Line Progression in mCRPC With HRR Mutations

Olaparib/Abiraterone Shows rPFS Benefit in mCRPC Regardless of HRR Status

May 31, 2023

During a Targeted Oncology™ Case-Based Roundtable™ event, Alicia K. Morgans, MD, MPH, discussed results of the phase 3 PROpel trial of patients with metastatic castration-resistant prostate cancer. This is the second of 2 articles based on this event.

Physicians Discuss When to Use a PARP Inhibitor in mCRPC

May 22, 2023

During a Targeted Oncology™ Case-Based Roundtable™ event, Alicia K. Morgans, MD, MPH, and participants discussed situations when they would use a PARP inhibitor to treat patients with metastatic castration-resistant prostate cancer in the second or third line. This is the first of 2 articles based on this event.